Pharmacology, clinical efficacy and safety of lamivudine in hepatitis B virus infection

References

• Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J. Viral Hepatol.11, 97–107 (2004).
   PubMed Web of Science ®Google Scholar
• Chen CJ, Yang HI, Su J et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level JAMA295, 65–73 (2006).
   PubMed Web of Science ®Google Scholar
• Iloeje UH, Yang HI, Su J et al. Predicting cirrhosis risk based on level of circulating hepatitis B viral load. Gastroenterology130, 678–686 (2006).
   PubMed Web of Science ®Google Scholar
• Mommeja-Marin H, Mondou E, Blum MR, Rousseau F. Serum HBV DNA as a marker of efficacy during therapy for chronic HBV infection: analysis and review of the literature. Hepatology37, 1309–1319 (2003).
   PubMed Web of Science ®Google Scholar
• Dienstag JL, Goldin RD, Heathcote EJ et al. Histological outcome during long-term lamivudine therapy. Gastroenterology124, 105–117 (2003).
   PubMed Web of Science ®Google Scholar
• Lai CL, Shouval D, Lok AS et al. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N. Engl. J. Med.354, 1011–1020 (2006).
   PubMed Web of Science ®Google Scholar
• Chang TT, Gish RG, de Man R et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N. Engl. J. Med.354, 1001–1010 (2006).
   PubMed Web of Science ®Google Scholar
• Lok ASF, McMahon BJ. Chronic hepatitis B. Hepatology45, 507–539 (2007).
   PubMed Web of Science ®Google Scholar
• Keeffe EB, Zeuzem S, Koff RS et al. Report of an international workshop: Roadmap for management of patients receiving oral therapy for chronic hepatitis B. Clin. Gastroenterol. Hepatol.5(8), 890–897 (2007).
   PubMed Web of Science ®Google Scholar
• Johnson MA, Moore KH, Yuen GJ, Bye A, Pakes GE. Clinical pharmacokinetics of lamivudine. Clin. Pharmacokinet.36(1), 41–66 (1999).
   PubMed Web of Science ®Google Scholar
• Johnson MA, Verpooten GA, Daniel MJ et al. Single dose pharmacokinetics of lamivudine in subjects with impaired renal function and the effect of haemodialysis. Br. J. Clin. Pharmacol.46, 21–27 (1998).
   PubMed Web of Science ®Google Scholar
• Heald AE, Hsyu PH, Yuen GJ, Robinson P, Mydlow P, Bartlett JA. Pharmacokinetics of lamivudine in human immunodeficiency virus-infected patients with renal dysfunction. Antimicrob. Agents Chemother.40, 1514–1519 (1996).
   PubMed Web of Science ®Google Scholar
• Bohjanen PR, Johnson MD, Szczech LA et al. Steady-state pharmacokinetics of lamivudine in human immunodeficiency virus-infected patients with end-stage renal disease receiving chronic dialysis. Antimicrob. Agents Chemother.46(8), 2387–2392 (2002).
   PubMed Web of Science ®Google Scholar
• Johnson MA, Horak J, Breuel P. The pharmacokinetics of lamivudine in patients with impaired hepatic function. Eur. J. Clin. Pharmacol.54(4), 363–366 (1998).
   PubMed Web of Science ®Google Scholar
• Sokal EM, Roberts EA, Mieli-Vergani G et al. A dose ranging study of the pharmacokinetics, safety, and preliminary efficacy of lamivudine in children and adolescents with chronic hepatitis B. Antimicrob. Agents Chemother.44(3), 590–597 (2000).
   PubMed Web of Science ®Google Scholar
• Johnson MA, Jenkins JM, Bye C. A study of the pharmacokinetic interaction between lamivudine and α IFN. Eur. J. Clin. Pharmacol.56(4), 289–292 (2000).
   PubMedGoogle Scholar
• Doong SL, Tsai CH, Schinazit RF, Liottat DC, Cheng YC. Inhibition of the replication of hepatitis B virus in vitro by 2´,3´-dideoxy-3´-thiacytidine and related analogues. Proc. Natl Acad. Sci. USA88, 8495–8499 (1991).
   PubMed Web of Science ®Google Scholar
• Lai CL, Chien RN, Leung NW et al. A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. N. Engl. J. Med.339, 61–68 (1998).
   PubMed Web of Science ®Google Scholar
• Dienstag JL, Schiff ER, Wright TL et al. Lamivudine as initial treatment for chronic hepatitis B in the United States. N. Engl. J. Med.341, 1256–1263 (1999).
   PubMed Web of Science ®Google Scholar
• Liaw YF, Leung NW, Chang TT et al. Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. Gastroenterology119, 172–180 (2000).
   PubMed Web of Science ®Google Scholar
• Leung NW, Lai CL, Chang TT et al. Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy. Hepatology33, 1527–1532 (2001).
   PubMed Web of Science ®Google Scholar
• Chang TT, Lai CL, Chien RN et al. Four years of lamivudine treatment in Chinese patients with chronic hepatitis B. J. Gastroenterol. Hepatol.19, 1276–1282 (2004).
   PubMed Web of Science ®Google Scholar
• Lok AS, Lai CL, Leung N et al. Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology125, 1714–1722 (2003).
   PubMed Web of Science ®Google Scholar
• Yuen MF, Fong DY, Wong DK, Yuen JC, Fung J, Lai CL. Hepatitis B virus DNA levels at week 4 of lamivudine treatment predict the 5-year ideal response. Hepatology46, 1695–1703 (2007).
   PubMed Web of Science ®Google Scholar
• Perrillo RP, Lai CL, Liaw YF et al. Predictors of HBeAg loss after lamivudine treatment for chronic hepatitis B. Hepatology36, 186–194 (2002).
   PubMed Web of Science ®Google Scholar
• Liaw YF, Tsai SL, Chien RN, Yeh CT, Chu CM. Prednisolone priming enhances Th1 response and efficacy of subsequent lamivudine therapy in patients with chronic hepatitis B. Hepatology32(3), 604–609 (2000).
   PubMedGoogle Scholar
• Sarin SK, Sandhu BS, Sharma BC, Jain M, Singh J, Malhotra V. Beneficial effects of ‘lamivudine pulse’ therapy in HBeAg-positive patients with normal ALT. J. Viral Hepatol.11(6), 552–558 (2004).
   PubMedGoogle Scholar
• Jonas MM, Kelley DA, Mizerski J et al. Clinical trial of lamivudine in children with chronic hepatitis B. N. Engl. J. Med.346, 1706–1713 (2002).
   PubMed Web of Science ®Google Scholar
• Sokal EM, Kelly DA, Mizerski J et al. Long-term lamivudine therapy for children with HBeAg-positive chronic hepatitis B. Hepatology43, 225–232 (2006).
   PubMed Web of Science ®Google Scholar
• Tassopoulos NC, Volpes R, Pastore G et al.; Lamivudine Precore Mutant Study Group. Efficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B. Hepatology29, 889–896 (1999).
   PubMed Web of Science ®Google Scholar
• Santantonio T, Mazzola M, Iacovazzi T, Miglietta A, Guastadisegni A, Pastore G. Long-term follow-up of patients with anti-HBe/HBV DNA positive chronic hepatitis B treated for 12 months with lamivudine. J. Hepatol.32, 300–306 (2000).
   PubMed Web of Science ®Google Scholar
• Lok AS, Hussain M, Cursano C et al. Evolution of hepatitis B virus polymerase gene mutations in hepatitis B e antigen-negative patients receiving lamivudine therapy. Hepatology32, 1145–1153 (2000).
   PubMed Web of Science ®Google Scholar
• Hadziyannis SJ, Papatheodoridis GV, Dimou E, Laras A, Papaioannou C. Efficacy of long-term lamivudine monotherapy in patients with hepatitis B e antigen-negative chronic hepatitis B. Hepatology32, 847–851 (2000).
   PubMed Web of Science ®Google Scholar
• Lau DT, Khokhar MF, Doo E et al. Long-term therapy of chronic hepatitis B with lamivudine. Hepatology32, 828–834 (2000).
   PubMed Web of Science ®Google Scholar
• Rizzetto M, Volpes R, Smedile A. Response of pre-core mutant chronic hepatitis B infection to lamivudine. J. Med. Virol.61, 398–402 (2000).
   PubMed Web of Science ®Google Scholar
• Papatheodoridis GV, Dimou E, Laras A, Papadimitropoulos V, Hadziyannis SJ. Course of virologic breakthroughs under long-term lamivudine in HBeAg-negative precore mutant HBV liver disease. Hepatology36, 219–226 (2002).
   PubMed Web of Science ®Google Scholar
• Papatheodoridis GV, Dimou E, Dimakopoulos K et al. Outcome of hepatitis B e antigen-negative chronic hepatitis B on long-term nucleos(t)ide analog therapy starting with lamivudine. Hepatology42, 121–129 (2005).
   PubMed Web of Science ®Google Scholar
• Chan HL, Wang H, Niu J, Chim AM, Sung JJ. Two-year lamivudine treatment for hepatitis B e antigen-negative chronic hepatitis B: a double-blind, placebo-controlled trial. Antivir. Ther.12(3), 345–353 (2007).
   PubMed Web of Science ®Google Scholar
• Schiff ER, Dienstag JL, Karayalcin S et al. Lamivudine and 24 weeks of lamivudine/IFN combination therapy for hepatitis B e antigen-positive chronic hepatitis B in IFN nonresponders. J. Hepatol.38, 818–826 (2003).
   PubMed Web of Science ®Google Scholar
• Liaw YF, Sung JJ, Chow WC et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N. Engl. J. Med.351, 1521–1531 (2004).
   PubMed Web of Science ®Google Scholar
• Perrillo RP, Wright T, Rakela J et al. A multicenter United States-Canadian trial to assess lamivudine monotherapy before and after liver transplantation for chronic hepatitis B. Hepatology33, 424–432 (2001).
   PubMed Web of Science ®Google Scholar
• Villeneuve JP, Condreay LD, Willems B et al. Lamivudine treatment for decompensated cirrhosis resulting from chronic hepatitis B. Hepatology31, 207–210 (2000).
   PubMed Web of Science ®Google Scholar
• Fontana RJ, Hann HW, Perrillo RP et al. Determinants of early mortality in patients with decompensated chronic hepatitis B treated with antiviral therapy. Gastroenterology123, 719–727 (2002).
   PubMed Web of Science ®Google Scholar
• Sarin SK, Kumar M, Kumar R et al. Higher efficacy of sequential therapy with IFN-α and lamivudine combination compared to lamivudine monotherapy in HBeAg positive chronic hepatitis B patients. Am. J. Gastroenterol.100(11), 2463–2471 (2005).
   PubMed Web of Science ®Google Scholar
• Song BC, Suh DJ, Lee HC, Chung YH, Lee YS. Hepatitis B e antigen seroconversion after lamivudine therapy is not durable in patients with chronic hepatitis B in Korea. Hepatology32, 803–806 (2000).
   PubMed Web of Science ®Google Scholar
• Lee KM, Cho SW, Kim SW, Kim HJ, Hahm KB, Kim JH. Effect of virological response on post-treatment durability of lamivudine-induced HBeAg seroconversion. J. Viral Hepatol.9, 208–212 (2002).
   PubMed Web of Science ®Google Scholar
• Dienstag JL, Cianciara J, Karayalcin S et al. Durability of serologic response after lamivudine treatment of chronic hepatitis B. Hepatology37, 748–755 (2003).
   PubMed Web of Science ®Google Scholar
• Ryu SH, Chung YH, Choi MH et al. Long-term additional lamivudine therapy enhances durability of lamivudine-induced HBeAg loss: a prospective study. J. Hepatol.39, 614–619 (2003).
   PubMed Web of Science ®Google Scholar
• Chien RN, Yeh CT, Tsai SL, Chu CM, Liaw YF. Determinants for sustained HBeAg response to lamivudine therapy. Hepatology38, 1267–1273 (2003).
   PubMed Web of Science ®Google Scholar
• Fung SK, Wong F, Hussain M, Lok AS. Sustained response after a 2-year course of lamivudine treatment of hepatitis B e antigen-negative chronic hepatitis B. J. Viral Hepatol.11, 432–438 (2004).
   PubMed Web of Science ®Google Scholar
• Dienstag JL, Goldin RD, Heathcote EJ et al. Histological outcome during long-term lamivudine therapy. Gastroenterology124, 105–117 (2003).
   PubMed Web of Science ®Google Scholar
• Di Marco V, Marzano A, Lampertico P et al. Clinical outcome of HBeAg-negative chronic hepatitis B in relation to virological response to lamivudine. Hepatology40, 883–891 (2004).
   PubMed Web of Science ®Google Scholar
• Yuen MF, Sablon E, Hui CK, Yuan HJ, Decraemer H, Lai CL. Factors associated with hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapy. Hepatology34, 785–791 (2001).
   PubMed Web of Science ®Google Scholar
• Lai CL, Gane E, Liaw YF et al. Telbivudine versus lamivudine in patients with chronic hepatitis B. N. Engl. J. Med.357(25), 2576–2588 (2007).
   PubMed Web of Science ®Google Scholar
• Su GG, Pan KH, Zhao NF, Fang SH, Yang DH, Zhou Y. Efficacy and safety of lamivudine treatment for chronic hepatitis B in pregnancy. World J. Gastroenterol.10, 910–912 (2004).
   PubMed Web of Science ®Google Scholar
• van Zonneveld M, van Nunen AB, Niesters HG, de Man RA, Schalm SW, Janssen HL. Lamivudine treatment during pregnancy to prevent perinatal transmission of hepatitis B virus infection. J. Viral Hepatol.10, 294–297 (2003).
   PubMed Web of Science ®Google Scholar
• Kazim SN, Wakil SM, Khan LA, Hasnain SE, Sarin SK. Vertical transmission of hepatitis B virus despite maternal lamivudine therapy. Lancet359(9316), 1488–1489 (2002).
   PubMed Web of Science ®Google Scholar
• Xu WM, Cui YT, Wang L et al. Efficacy and safety of lamivudine in late pregnancy for the prevention of mother–child transmission of hepatitis B: a multicenter, randomized, double-blind, placebo-controlled study. Program and abstracts of the 55th Annual Meeting of the American Association for the Study of Liver Diseases. Boston, MA, USA, 29 October–2 November 2004 (Abstract 246).
   Google Scholar
• Yeo W, Chan PK, Hui P et al. Hepatitis B virus reactivation in breast cancer patients receiving cytotoxic chemotherapy: a prospective study. J. Med. Virol.70, 553–561 (2003).
   PubMed Web of Science ®Google Scholar
• Niscola P, Del Principe M, Maurillo L et al. Fulminant B hepatitis in a surface antigen-negative patient with B-cell chronic lymphocytic leukaemia after rituximab therapy. Leukemia19, 1840–1841 (2005).
   PubMed Web of Science ®Google Scholar
• Blanpain C, Knoop C, Delforge M et al. Reactivation of hepatitis B after transplantation in patients with pre-existing anti-hepatitis B surface antigen antibodies: report on three cases and review of the literature. Transplantation66, 883–886 (1998).
   PubMed Web of Science ®Google Scholar
• Hui CK, Cheung WW, Zhang HY et al. Kinetics and risk of de novo hepatitis B infection in HBsAg-negative patients undergoing cytotoxic chemotherapy. Gastroenterology131, 59–68 (2006).
   PubMed Web of Science ®Google Scholar
• Katz LH, Fraser A, Gafter-Gvili A, Leibovici L, Tur-Kaspa R. Lamivudine prevents reactivation of hepatitis B and reduces mortality in immunosuppressed patients: systematic review and meta-analysis. J. Viral Hepatol.15, 89–102 (2008).
   PubMed Web of Science ®Google Scholar
• Kohrt HE, Ouyang DL, Keeffe EB. Systematic review: lamivudine prophylaxis for chemotherapy-induced reactivation of chronic hepatitis B virus infection. Aliment. Pharmacol Ther.24, 1003–1016 (2006).
   PubMed Web of Science ®Google Scholar
• Lau GK, Yiu HH, Fong DY et al. Early is superior to deferred preemptive lamivudine therapy for hepatitis B patients undergoing chemotherapy. Gastroenterology125, 1742–1749 (2003).
   PubMed Web of Science ®Google Scholar
• Hui CK, Cheung WW, Au WY et al. Hepatitis B reactivation after withdrawal of pre-emptive lamivudine in patients with haematological malignancy on completion of cytotoxic chemotherapy. Gut54, 1597–1603 (2005).
   PubMed Web of Science ®Google Scholar
• Schreibman IR, Schiff ER. Prevention and treatment of recurrent hepatitis B after liver transplantation: the current role of nucleoside and nucleotide analogues. Ann. Clin. Microbiol. Antimicrob.5, 8 (2006).
   PubMedGoogle Scholar
• Terrault N, Roche B, Samuel D. Management of the hepatitis B virus in the liver transplantation setting: a European and an American perspective. Liver Transpl.11(7), 716–732 (2005).
   PubMed Web of Science ®Google Scholar
• Markowitz JS, Martin P, Conrad AJ et al. Prophylaxis against hepatitis B recurrence following liver transplantation using combination lamivudine and hepatitis B immune globulin. Hepatology28(2), 585–589 (1998).
   PubMed Web of Science ®Google Scholar
• Han SH, Ofman J, Holt C et al. An efficacy and cost–effectiveness analysis of combination hepatitis B immune globulin and lamivudine to prevent recurrent hepatitis B after orthotopic liver transplantation compared with hepatitis B immune globulin monotherapy. Liver Transpl.6(6), 741–748 (2000).
   PubMed Web of Science ®Google Scholar
• Marzano A, Salizzoni M, Debernardi-Venon W et al. Prevention of hepatitis B virus recurrence after liver transplantation in cirrhotic patients treated with lamivudine and passive immunoprophylaxis. J. Hepatol.34(6), 903–910 (2001).
   PubMed Web of Science ®Google Scholar
• Steinmuller T, Seehofer D, Rayes N et al. Increasing applicability of liver transplantation for patients with hepatitis B-related liver disease. Hepatology35(6), 1528–1535 (2002).
   PubMed Web of Science ®Google Scholar
• Dumortier J, Chevallier P, Scoazec JY, Berger F, Boillot O. Combined lamivudine and hepatitis B immunoglobulin for the prevention of hepatitis B recurrence after liver transplantation: long-term results. Am. J. Transplant.3(8), 999–1002 (2003).
   PubMed Web of Science ®Google Scholar
• Yao FY, Osorio RW, Roberts JP et al. Intramuscular hepatitis B immune globulin combined with lamivudine for prophylaxis against hepatitis B recurrence after liver transplantation. Liver Transpl. Surg.5(6), 491–496 (1999).
   PubMedGoogle Scholar
• Anselmo DM, Ghobrial RM, Jung LC et al. New era of liver transplantation for hepatitis B: a 17-year single-center experience. Ann. Surg.235(5), 611–619 (2002).
   PubMed Web of Science ®Google Scholar
• Zheng S, Chen Y, Liang T et al. Prevention of hepatitis B recurrence after liver transplantation using lamivudine or lamivudine combined with hepatitis B immunoglobulin prophylaxis. Liver Transpl.12(2), 253–258 (2006).
   PubMed Web of Science ®Google Scholar
• Yan ML, Yan LN, Li B et al. Intramuscular hepatitis B immune globulin combined with lamivudine in prevention of hepatitis B recurrence after liver transplantation. Hepatobiliary Pancreat. Dis. Int.5(3), 360–363 (2006).
   PubMedGoogle Scholar
• Gane EJ, Angus PW, Strasser S et al. Lamivudine plus lowdose hepatitis B immunoglobulin to prevent recurrent hepatitis B following liver transplantation. Gastroenterology132(3), 931–937 (2007).
   PubMed Web of Science ®Google Scholar
• Buti M, Antonio M, Prieto M et al. A randomized study comparing lamivudine monotherapy after a short course of hepatitis B immune globulin (HBIg) and lamivudine with long-term lamivudine plus HBIg in the prevention of hepatitis B virus recurrence after liver transplantation. J. Hepatol.38(6), 811–817 (2003).
   PubMed Web of Science ®Google Scholar
• Neff GW, O’Brien CB, Nery J et al. Outcomes in liver transplant recipients with hepatitis B virus: resistance and recurrence patterns from a large transplant center over the last decade. Liver Transpl.10, 1372–1378 (2004).
   PubMedGoogle Scholar
• Wong SN, Chu CJ, Wai CT et al. Low risk of hepatitis B virus recurrence after withdrawal of long-term hepatitis B immunoglobulin in patients receiving maintenance nucleos(t)ide analogue therapy. Liver Transpl.13(3), 374–381 (2007).
   PubMed Web of Science ®Google Scholar
• Perillo R, Rakela J, Dienstag J et al. Multicenter study of lamivudine therapy for hepatitis B after liver transplantation. Hepatology29, 1581–1586 (1999).
   PubMedGoogle Scholar
• Rayes N, Seehofer D, Hopf U et al. Comparison of famciclovir and lamivudine in the long-term treatment of hepatitis B infection after liver transplantation. Transplantation71, 96–101 (2001).
   PubMedGoogle Scholar
• Fontana RJ, Hann HW, Wright T et al. A multicenter study of lamivudine treatment in 33 patients with hepatitis B after liver transplantation. Liver Transpl.6, 504–510 (2001).
   Google Scholar
• Schiff ER, Lai CL, Hadziyannis S et al. Adefovir dipivoxil therapy for lamivudine-resistant hepatitis B in pre- and postliver transplantation patients. Hepatology38(6), 1419–1427 (2003).
   PubMed Web of Science ®Google Scholar
• Tan J, Lok AS. Antiviral therapy for pre- and post-liver transplantation patients with hepatitis B. Liver Transpl.13(3), 323–326 (2007).
   PubMedGoogle Scholar
• Girndt M, Kohler H. Hepatitis B virus infection in hemodialysis patients. Semin. Nephrol.22, 340–350 (2002).
   PubMed Web of Science ®Google Scholar
• Kletzmayr J, Watschinger B, Müller C et al. Twelve months of lamivudine treatment for chronic hepatitis B virus infection in renal transplant recipients. Transplantation70(9), 1404–1407 (2000).
   PubMedGoogle Scholar
• Viganò M, Colombo M, Aroldi A et al. Long-term lamivudine monotherapy in renal-transplant recipients with hepatitis-B-related cirrhosis. Antivir. Ther.10(6), 709–713 (2005).
   PubMedGoogle Scholar
• Han DJ, Kim TH, Park SK et al. Results on preemptive or prophylactic treatment of lamivudine in HBsAg+ renal allograft recipients: comparison with salvage treatment after hepatic dysfunction with HBV recurrence. Transplantation71(3), 387–394 (2001).
   PubMedGoogle Scholar
• Benhamou Y, Katlama C, Lunel F et al. Effects of lamivudine on replication of hepatitis B virus in HIV-infected men. Ann. Intern. Med.125, 705–712 (1996).
   PubMed Web of Science ®Google Scholar
• Dore GJ, Cooper DA, Barrett C et al.; the CAESAR Coordinating Committee. Dual efficacy of lamivudine treatment in human immunodeficiency virus/hepatitis B virus-coinfected persons in a randomized, controlled study (CAESAR). J. Infect. Dis.180, 607–613 (1999).
   PubMed Web of Science ®Google Scholar
• CAESAR Coordinating Committee. Randomised trial of addition of lamivudine or lamivudine plus loviride to zidovudine-containing regimens for patients with HIV-1 infection: the CAESAR trial. Lancet349, 1413–1421 (1997).
   PubMedGoogle Scholar
• Sulkowski MS. Viral hepatitis and HIV coinfection. J. Hepatol.48, 353–367 (2008).
   PubMed Web of Science ®Google Scholar
• Castells L, Vargas V, Rodriguez F et al. Clinical impact and efficacy of lamivudine therapy in de novo hepatitis B infection after liver transplantation. Liver Transpl.8, 892–900 (2002).
   PubMedGoogle Scholar
• Schmilovitz-Weiss H, Ben-Ari Z, Sikuler E et al. Lamivudine treatment for acute severe hepatitis B: a pilot study. Liver Int.24, 547–551 (2004).
   PubMed Web of Science ®Google Scholar
• Tillman HL, Wedemeyer H, Hadem J et al. Early lamuvidine therapy may prevent liver failure in patients with fulminant hepatitis B. Hepatology36, 375A (2002).
   Google Scholar
• Kumar M, Satapathy S, Mongia R et al. A randomized controlled trial of lamivudine to treat acute hepatitis B. Hepatology45, 97–101 (2007).
   PubMed Web of Science ®Google Scholar
• Hou J, Yin YK, Xu D et al. Telbivudine versus lamivudine in Chinese patients with chronic hepatitis B: results at 1 year of a randomized, double-blind trial. Hepatology47(2), 447–454 (2008).
   PubMed Web of Science ®Google Scholar
• Gish RG, Lok AS, Chang TT et al. Entecavir therapy for up to 96 weeks in patients with HBeAg-positive chronic hepatitis B. Gastroenterology133(5), 1437–1444 (2007).
   PubMed Web of Science ®Google Scholar
• Cooksley WG, Piratvisuth T, Lee SD et al. PegIFN α-2a (40 kDa): an advance in the treatment of hepatitis B e antigen-positive chronic hepatitis B. J. Viral Hepatol.10, 298–305 (2003).
   PubMed Web of Science ®Google Scholar
• Lau GK, Piratvisuth T, Luo KX et al. PegIFN α-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N. Engl. J. Med.352, 2682–2695 (2005).
   PubMed Web of Science ®Google Scholar
• Janssen HL, van Zonneveld M, Senturk H et al. Pegylated IFN -2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomized trial. Lancet365, 123–129 (2005).
   PubMed Web of Science ®Google Scholar
• Chan HL, Leung NW, Hui AY et al. A randomized, controlled trial of combination therapy for chronic hepatitis B: comparing pegylated IFN-α2b and lamivudine with lamivudine alone. Ann. Intern. Med.142, 240–250 (2005).
   PubMed Web of Science ®Google Scholar
• Marcellini P, Lau GK, Bonino F et al. PegIFN α-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N. Engl. J. Med.351, 1206–1217 (2004).
   PubMedGoogle Scholar
• Schalm SW, Heathcote J, Cianciara J et al. Lamivudine and α IFN combination treatment of patients with chronic hepatitis B infection: a randomised trial. Gut46, 562–568 (2000).
   PubMed Web of Science ®Google Scholar
• Barbaro G, Zechini F, Pellicelli AM et al. Long-term efficacy of IFN α-2b and lamivudine in combination compared to lamivudine monotherapy in patients with chronic hepatitis B. An Italian multicenter, randomized trial. J. Hepatol.35, 406–411 (2001).
   PubMed Web of Science ®Google Scholar
• Yalcin K, Degertekin H, Yildiz F, Celik Y. Comparison of 12-month courses of IFN-α-2b-lamivudine combination therapy and IFN-α-2b monotherapy among patients with untreated chronic hepatitis B. Clin. Infect. Dis.36, 1516–1522 (2003).
   PubMedGoogle Scholar
• Hasan F, al-Khaldi J, Asker H et al. Treatment of chronic hepatitis B with the sequential administration of IFN and lamivudine. Hepatogastroenterology50, 2040–2042 (2003).
   PubMedGoogle Scholar
• Deng H, Zhao ZX, Xu QH, Zhou YP, Chen YM, Yao JL. Therapy effect of lamivudine combination with α IFN on patients with chronic hepatitis B. Zhonghua Gan Zang Bing Za Zhi11(5), 305–308 (2003).
   PubMedGoogle Scholar
• Ayaz C, Celen MK, Colak H, Hosoglu S, Geyik MF. Comparison of lamivudine and α-IFN combination with α-IFN alone in the treatment of HBeAg-positive chronic hepatitis B. Indian J. Gastroenterol.25(2), 71–73 (2006).
   PubMedGoogle Scholar
• Manesis EK, Papatheodoridis GV, Hadziyannis SJ. A partially overlapping treatment course with lamivudine and IFN in hepatitis B e antigen-negative chronic hepatitis B. Aliment. Pharmacol. Ther.23(1), 99–106 (2006).
   PubMed Web of Science ®Google Scholar
• Tatulli I, Francavilla R, Rizzo GL et al. Lamivudine and α-IFN in combination long term for precore mutant chronic hepatitis B. J. Hepatol.35(6), 805–810 (2001).
   PubMed Web of Science ®Google Scholar
• Economou M, Manolakopoulos S, Trikalinos TA et al. IFN-α plus lamivudine vs lamivudine reduces breakthroughs, but does not affect sustained response in HBeAg negative chronic hepatitis B. World J. Gastroenterol.11(37), 5882–5887 (2005).
   PubMed Web of Science ®Google Scholar
• Yurdaydin C, Bozkaya H, Cetinkaya H et al. Lamivudine vs lamivudine and IFN combination treatment of HBeAg(-) chronic hepatitis B. J. Viral Hepatol.12(3), 262–268 (2005).
   PubMedGoogle Scholar
• Santantonio T, Niro GA, Sinisi E et al. Lamivudine/IFN combination therapy in anti-HBe positive chronic hepatitis B patients: a controlled pilot study. J. Hepatol.36(6), 799–804 (2002).
   PubMed Web of Science ®Google Scholar
• Karabay O, Tamer A, Tahtaci M, Vardi S, Celebi H. Effectiveness of lamivudine and IFN-α combination therapy versus IFN-α monotherapy for the treatment of HBeAg-negative chronic hepatitis B patients: a randomized clinical trial. J. Microbiol. Immunol. Infect.38, 262–266 (2005).
   PubMedGoogle Scholar
• Nikolaidis NL, Giouleme OI, Tziomalos KA et al. IFN/long-term lamivudine combination therapy in anti-HBe positive chronic hepatitis B patients. J. Gastroenterol. Hepatol.20(11), 1721–1725 (2005).
   PubMed Web of Science ®Google Scholar
• van Zonneveld M, Zondervan PE, Cakaloglu Y et al. HBV 99–01 Study Group. PegIFN improves liver histology in patients with HBeAg-positive chronic hepatitis B: no additional benefit of combination with lamivudine. Liver Int. 2006 26(4), 399–405 (2006).
   PubMed Web of Science ®Google Scholar
• Chan HLY, Hui AY, Wong VW, Chim AM, Wong ML, Sung JJ. Long-term follow-up of pegIFN and lamivudine combination treatment in HBeAg-positive chronic hepatitis B. Hepatology41, 1357–1364 (2005).
   PubMed Web of Science ®Google Scholar
• Kaymakoglu S, Oguz D, Gur G et al. Pegylated IFN α-2b monotherapy and pegylated IFN α-2b plus lamivudine combination therapy for patients with hepatitis B virus E antigen-negative chronic hepatitis B. Antimicrob. Agents Chemother.51(8), 3020–3022 (2007).
   PubMed Web of Science ®Google Scholar
• Vassiliadis T, Tziomalos K, Patsiaoura K et al. Lamivudine/pegylated IFN α-2b sequential combination therapy compared with lamivudine monotherapy in HBeAg-negative chronic hepatitis B. J. Gastroenterol. Hepatol.22(10), 1582–1588 (2007).
   PubMedGoogle Scholar
• Rudin D, Shah SM, Kiss A, Wetz RV, Sottile VM. IFN and lamivudine vs. IFN for hepatitis B e antigen-positive hepatitis B treatment: meta-analysis of randomized controlled trials. Liver Int.27(9), 1185–1193 (2007).
   PubMedGoogle Scholar
• Ruden D. Lamivudine and IFN versus lamivudine monotherapy for HBeAg-positive hepatitis B treatment: a meta-analysis of randomized, controlled trials. Adv. Ther.24(4), 784–795 (2007).
   PubMedGoogle Scholar
• Jang MK, Chung YH, Choi MH et al. Combination of α-IFN with lamivudine reduces viral breakthrough during long-term therapy. J. Gastroenterol. Hepatol.19(12), 1363–1368 (2004).
   PubMedGoogle Scholar
• Lau GKK, Tsiang M, Hou J et al. Combination therapy with lamivudine and famciclovir for chronic hepatitis B infected Chinese: a viral dynamics study. Hepatology32, 394–399 (2000).
   PubMed Web of Science ®Google Scholar
• Lai CL, Leung N, Teo EK et al.; Telbivudine Phase II Investigator Group. A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B. Gastroenterology129(2), 528–536 (2005).
   PubMed Web of Science ®Google Scholar
• Lim SG, Krastev Z, Ng TM et al. Randomized, double-blind study of emtricitabine (FTC) plus clevudine versus FTC alone in treatment of chronic hepatitis B. Antimicrob. Agents Chemother.50(5), 642–648 (2006).
   Google Scholar
• Stuyver LJ, Locarnini SA, Lok A et al. Nomenclature for antiviral-resistant human hepatitis B virus mutations in the polymerase region. Hepatology33, 751–757 (2001).
   PubMed Web of Science ®Google Scholar
• Bartholomeusz A, Tehan BG, Chalmers DK. Comparisons of the HBV and HIV polymerase, and antiviral resistance mutations. Antivir. Ther.9, 149–160 (2004).
   PubMedGoogle Scholar
• Ono SK, Kato N, Shiratori Y et al. The polymerase L528M mutation cooperates with nucleotide binding-site mutations, increasing hepatitis B virus replication and drug resistance. J. Clin. Invest.107, 449–455 (2001).
   PubMed Web of Science ®Google Scholar
• Delaney WE, Yang H, Westland CE et al. The hepatitis B virus polymerase mutation rtV173L is selected during lamivudine therapy and enhances viral replication in vitro. J. Virol.77, 11833–11841 (2003).
   PubMed Web of Science ®Google Scholar
• Yatsuji H, Noguchi C, Hiraga N et al. Emergence of a novel lamivudine-resistant hepatitis B virus variant with a substitution outside the YMDD motif. Antimicrob. Agents Chemother.50, 3867–3874 (2006).
   PubMed Web of Science ®Google Scholar
• Tenney DJ, Levine SM, Rose RE et al. Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to lamivudine. Antimicrob. Agents Chemother.48, 3498–3507 (2004).
   PubMed Web of Science ®Google Scholar
• Brunelle MN, Jacquard AC, Pichoud C et al. Susceptibility to antivirals of a human HBV strain with mutations conferring resistance to both lamivudine and adefovir. Hepatology41, 1391–1398 (2005).
   PubMed Web of Science ®Google Scholar
• Lim SG, Ng TM, Kung N et al. A double-blind placebo-controlled study of emtricitabine in chronic hepatitis B. Arch. Intern. Med.166, 49–56 (2006).
   PubMed Web of Science ®Google Scholar
• Seigneres B, Pichoud C, Martin P, Furman P, Trepo C, Zoulim F. Inhibitory activity of dioxolane purine analogs on wild-type and lamivudine-resistant mutants of hepadnaviruses. Hepatology36, 710–722 (2002).
   PubMed Web of Science ®Google Scholar
• Ladner S, Miller T, Otto M, King R. The hepatitis B virus M539V polymerase variation responsible for 3TC resistance also confers cross-resistance to other nucleoside analogues. Antivir. Chem. Chemother.9, 65–72 (1998).
   PubMed Web of Science ®Google Scholar
• Chin R, Shaw T, Torresi J et al. In vitro susceptibilities of wild-type or drug-resistant hepatitis B virus to (-)-β-D-2, 6-diaminopurine dioxolane and 2-fluoro-5-methyl-β-L-arabinofuranosyluracil. Antimicrob. Agents Chemother.45, 2495–2501 (2001).
   PubMed Web of Science ®Google Scholar
• Yang H, Qi X, Sabogal A, Miller M, Xiong S, Delaney WET. Cross-resistance testing of next-generation nucleoside and nucleotide analogues against lamivudine-resistant HBV. Antivir. Ther.10, 625–633 (2005).
   PubMed Web of Science ®Google Scholar
• Helpertz RA Jr, Miller TJ, Kelley CM, Delaney WF, Locarnini SA, Isom HC. In vitro study of the effects of precore and lamivudine-resistant mutations on hepatitis B virus replication. J. Virol.81(7), 3068–3076 (2007).
   PubMedGoogle Scholar
• Liaw YF, Chien RN, Yeh CT. No benefit to continue lamivudine therapy after emergence of YMDD mutations. Antivir. Ther.9, 257–262 (2004).
   PubMed Web of Science ®Google Scholar
• Wong VW, Chan HL, Wong ML, Tam JS, Leung NW. Clinical course after stopping lamivudine in chronic hepatitis B patients with lamivudine-resistant mutants. Aliment. Pharmacol. Ther.19, 323–329 (2004).
   PubMedGoogle Scholar
• Perrillo R, Hann HW, Mutimer D et al. Adefovir dipivoxil added to ongoing lamivudine in chronic hepatitis B with YMDD mutant hepatitis B virus. Gastroenterology126, 81–90 (2004).
   PubMed Web of Science ®Google Scholar
• Peters MG, Hann HW, Martin P et al. Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B. Gastroenterology126, 91–101 (2004).
   PubMed Web of Science ®Google Scholar
• Yeon JE, Yoo W, Hong SP et al. Resistance to adefovir dipivoxil in lamivudine resistant chronic hepatitis B patients treated with adefovir dipivoxil. Gut55, 1488–1495 (2006).
   PubMed Web of Science ®Google Scholar
• Lampertico P, Vigano M, Manenti E, Iavarone M, Lunghi G, Colombo M. Adefovir rapidly suppresses hepatitis B in HBeAg-negative patients developing genotypic resistance to lamivudine. Hepatology42, 1414–1419 (2005).
   PubMed Web of Science ®Google Scholar
• Lampertico P, Viganò M, Manenti E, Iavarone M, Sablon E, Colombo M. Low resistance to adefovir combined with lamivudine: a 3-year study of 145 lamivudine-resistant hepatitis B patients. Gastroenterology133(5), 1445–1451 (2007).
   PubMed Web of Science ®Google Scholar
• Rapti I, Dimou E, Mitsoula P, Hadziyannis SJ. Adding-on versus switching to adefovir therapy in lamivudine resistant HBe antigen-negative chronic hepatitis B. Hepatology45, 307–313 (2007).
   PubMed Web of Science ®Google Scholar
• van Bommel F, Wunsche T, Mauss S et al. Comparison of adefovir and tenofovir in the treatment of lamivudine resistant hepatitis B virus infection. Hepatology40, 1421–1425 (2004).
   PubMed Web of Science ®Google Scholar
• Kuo A, Dienstag JL, Chung RT. Tenofovir disoproxil fumarate for the treatment of lamivudine-resistant hepatitis B. Clin. Gastroenterol. Hepatol.2, 266–272 (2004).
   PubMed Web of Science ®Google Scholar
• Chang T, Chish R, Hadziyannis S et al. A dose-ranging study of the efficacy and tolerability of entecavir in lamivudine-refractory chronic hepatitis B patients. Gastroenterology129, 1198–1209 (2005).
   PubMed Web of Science ®Google Scholar
• Colonno RJ, Rose R, Baldick CJ et al. Entecavir resistance is rare in nucleoside naive patients with hepatitis B. Hepatology44, 1656–1665 (2006).
   PubMed Web of Science ®Google Scholar